Mark Erlander

Mark Erlander

CEOatCardiff Oncology· In proxies 2022–2025

Pay in FY2025+26% from the year before · Cardiff Oncology stock -35.3% the same year

Mark Erlander was paid $3.0M in FY2025 (Dec), up 26%. Cardiff Oncology stock fell 35.3% that year.

Pay$100 in the stock at the end of FY21 → $47
Pay is from the Summary Compensation Table of each Cardiff Oncology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Cardiff OncologyPublic company · 4 yr
    • CEO2022 – Present · 4 yrStock in role -85%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?